



Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer

REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer.

Mr. Fitzpatrick brings more than 20 years of executive-level legal experience to his role as leader of Coherus' legal and compliance departments, reporting directly to Coherus President and CEO, Denny Lanfear. Mr. Fitzpatrick will serve as a member of the Company's executive leadership team and be involved in all legal matters.

"Tom brings a passion for our mission, strong leadership skills and deep litigation insights to this critical position," said Denny Lanfear, President and CEO of Coherus. "He is a highly successful complex patent and trade secrets case litigator, and has advised us as outside counsel, earning the trust and confidence of our management. Tom also has an accomplished history advising and litigating on behalf of growing companies. That experience, along with his IP expertise, are the perfect combination to help Coherus deliver on the company's next stage of growth as a commercial organization."

"Coherus is redefining the healthcare system in the most consequential way, providing access to life-changing biologic medicines while significantly reducing costs," said Fitzpatrick. "Coherus' commitment to patient care, innovation and trust is inspiring. As Coherus continues to grow, it will create new and expanding market opportunities. I'm thrilled to join the team at this exciting time."

Prior to Coherus, Fitzpatrick was an equity partner in large national and international law firms representing technology and life science companies. Earlier in his career, Fitzpatrick was a Deputy District Attorney in San Mateo, California. He earned his Juris Doctor from Santa Clara University School of Law and a Bachelor of Arts degree from the University of California, Berkeley.

About Coherus BioSciences, Inc.

Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus BioSciences is positioned as a leader in the global biosimilar marketplace. Coherus BioSciences commercializes UDENYCA™ (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA™ in the European Union. Coherus BioSciences is advancing two late-stage clinical products towards commercialization, CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), and developing a robust pipeline of future products in ophthalmology (including CHS-3351, a ranibizumab biosimilar, and CHS-2020, an aflibercept biosimilar), as well as CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visit www.coherus.com.

CONTACT:

David S. Arrington
Vice President, Investor Relations & Corporate Affairs
Coherus BioSciences, Inc.
darrington@coherus.com
+1 (650) 395-0196



Source: Coherus BioSciences, Inc.